Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

NCT02154529 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor closed the study due to lack of response.

Conditions

HER-2 Positive Breast Cancer
Metastatic Malignant Neoplasm to Brain

Interventions

DRUG: Tesevatinib
DRUG: Trastuzumab

Sponsor

Kadmon Corporation, LLC